A contentious report by the US government’s trade watchdog that reviews its trading partners’ intellectual property rights protection policies appears to tread more softly in its demands than it has in previous years, according to some non-governmental organisations. However, it still bars access to medicines by pushing countries to adopt IP protection standards equivalent to those in the US, they claim...
Please login to read the full article.Welcome:
IBI01 - Circulation
scr
RAJ Pharma
US 301 IP report takes softer approach, say NGOs
06 May 2010
Francesca Bruce
RELATED CONTENT
NEWS
RAJ Pharma News
Other Informa News
ANALYSIS
Other Informa Analysis
FEATURES
RAJ Pharma Features
Other Informa Features
COUNTRY PROFILES
RAJ Pharma Country Profiles
Other Informa Country Profiles
EVENTS
October 4th, 2010
London, UK
October 19th, 2010
Barcelona, Spain
October 20th, 2010
Barcelona, Spain